UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.929

Sortiert nach

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

Annals of oncology, 2021-12, Vol.32 (12), p.1637-1642

2021

Volltextzugriff (PDF)

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Annals of oncology, 2016-08, Vol.27 (8), p.1482-1492

2016

Volltextzugriff (PDF)

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Annals of oncology, 2016-04, Vol.27 (4), p.559-574

2016

Volltextzugriff (PDF)

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i28-i37

2018

Volltextzugriff (PDF)

Prioritizing targets for precision cancer medicine

Annals of oncology, 2014-12, Vol.25 (12), p.2295-2303

2014

Volltextzugriff (PDF)

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Annals of oncology, 2019-08, Vol.30 (8), p.1401-1403

2019

Volltextzugriff (PDF)

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Annals of oncology, 2018-04, Vol.29 (4), p.812-824

2018

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-01, Vol.24 (1), p.20-30

2013

Volltextzugriff (PDF)

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Annals of oncology, 2018-09, Vol.29 (9), p.1911-1917

2018

Volltextzugriff (PDF)

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Annals of oncology, 2014-11, Vol.25 (11), p.2244-2251

2014

Volltextzugriff (PDF)

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Annals of oncology, 2020-03, Vol.31 (3), p.430-434

2020

Volltextzugriff (PDF)

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Annals of oncology, 2016-02, Vol.27 (2), p.214-224

2016

Volltextzugriff (PDF)

Tumour stem cell-targeted treatment: elimination or differentiation

Annals of oncology, 2006-11, Vol.17 (11), p.1620-1624

2006

Volltextzugriff (PDF)

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Annals of oncology, 2017-07, Vol.28 (7), p.1523-1531

2017

Volltextzugriff (PDF)

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Annals of oncology, 2017-02, Vol.28 (2), p.254-269

2017

Volltextzugriff (PDF)

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Annals of oncology, 2020-03, Vol.31 (3), p.377-386

2020

Volltextzugriff (PDF)

Small cell lung cancer: a slightly less orphan disease after immunotherapy

Annals of oncology, 2021-06, Vol.32 (6), p.698-709

2021

Volltextzugriff (PDF)

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

Annals of oncology, 2017-04, Vol.28 (4), p.882-889

2017

Volltextzugriff (PDF)

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

European journal of cancer (1990), 2018-01, Vol.88, p.38-47

2018

Volltextzugriff (PDF)

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Annals of oncology, 2022-10, Vol.33 (10), p.1041-1051

2022

Volltextzugriff (PDF)

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

Annals of oncology, 2009-10, Vol.20 (10), p.1674-1681

2009

Volltextzugriff (PDF)

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1408-1415

2015

Volltextzugriff (PDF)

Detection of circulating tumour cells with a hybrid (epithelial mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

British journal of cancer, 2011-10, Vol.105 (9), p.1338-1341

2011

Volltextzugriff (PDF)

1 – 25 von 2.929

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.585)
Mit Volltextzugriff
(2.471)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(1.415)
EZB Electronic Journals Library
(1.321)
MEDLINE
(1.110)
Elsevier ScienceDirect Journals Complete
(981)
Ovid SocietyJournals and Single Titles
(885)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(466)
NUS Single-Journal Subscriptions
(407)
IngentaConnect Journals
(393)
Wiley Online Library Journals
(268)
Wiley Online Library
(185)
SpringerLink_现刊
(131)
Oxford journals
(90)
Nature_系列刊
(81)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(73)
JSTOR
(51)
IEEE Xplore
(50)
Oxford Journals 2020 Medicine
(42)
Nexis Uni
(37)
Taylor & Francis Online
(35)
eBooks on EBSCOhost
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Prioritizing targets for precision cancer medicine

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Tumour stem cell-targeted treatment: elimination or differentiation

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Small cell lung cancer: a slightly less orphan disease after immunotherapy

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Detection of circulating tumour cells with a hybrid (epithelial mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

Suchergebnisse filtern